Aoshang Pharmaceuticals (603229.SH) released its semi-annual results, with a net profit attributable to parent company shareholders of 169 million yuan, a year-on-year decrease of 5.83%.

Financial news from Zhitong: Alxa Pharmaceutical (603229.SH) disclosed its 2025 interim report. During the reporting period, the company achieved a revenue of 482 million yuan, a year-on-year decrease of 2.14%; net profit attributable to shareholders was 169 million yuan, a year-on-year decrease of 5.83%; non-recurring net profit was 151 million yuan, a year-on-year decrease of 12.29%; basic earnings per share was 0.20 yuan.